Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.

ABSTRACT:

Background

Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional indices.

Methods

A study was nested from phase 2b randomized double-blind controlled trial of Tanzanian patients who received a 600 mg, 900 mg, or 1200 mg with a standard dose for DS-TB. Serum at 6 weeks collected over 24-h at 2-h intervals was collected for rifampin area under the concentration-time curve relative to minimum inhibitory concentration (AUC_0-24/MIC) or peak concentration and MIC (C_max/MIC). TDA was the ratio of time-to-positive growth of the pat

SUBMITTER: Said BN 

PROVIDER: S-EPMC7612567 | biostudies-literature | 2021 Oct-Dec

REPOSITORIES: biostudies-literature